Glycoprotein non-metastatic melanoma protein B promotes tumor growth and is a biomarker for lymphangioleiomyomatosis
Endocrine-Related Cancer · 2024
DOI: 10.1530/erc-23-0312 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine-Related Cancer, 2024. Verfasst von Erin Gibbons und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology University of Rochester School of Medicine and Dentistry, Rochester, New York, USA. Hauptthemen laut MEDLINE: Lymphangioleiomyomatosis, Membrane Glycoproteins, Biomarkers, Tumor. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Lymphangioleiomyomatosis (LAM) is a rare, progressive cystic lung disease affecting almost exclusively female-sexed individuals. The cysts represent regions of lung destruction caused by smooth muscle tumors containing mutations in one of the two tuberous sclerosis ( TSC ) genes. mTORC1 inhibition slows but does not stop LAM advancement. Furthermore, monitoring disease progression is hindered by insufficient biomarkers. Therefore, new treatment options and biomarkers are needed. LAM cells express melanocytic markers, including glycoprotein non-metastatic melanoma protein B (GPNMB). The function of GPNMB in LAM is currently unknown; however, GPNMB’s unique cell surface expression on tumor versus benign cells makes GPNMB a potential therapeutic target, and persistent release of its extracellular ectodomain suggests potential as a serum biomarker. Here, we establish that GPNMB expression is dependent on mTORC1 signaling, and that GPNMB regulates TSC2-null tumor cell invasion in vitro . Further, we demonstrate that GPNMB enhances TSC2-null xenograft tumor growth in vivo , and that ectodomain release is required for this xenograft growth. We also show that GPNMB’s ectodomain is released from the cell surface of TSC2-null cells by proteases ADAM10 and 17, and we identify the protease target sequence on GPNMB. Finally, we demonstrate that GPNMB’s ectodomain is present at higher levels in LAM patient serum compared to healthy controls and that ectodomain levels decrease with mTORC1 inhibition, making it a potential LAM biomarker.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
- Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
- Division of Hematology and Oncology, UT Southwestern, Dallas, Texas, USA.
- Division of Pulmonary, Critical Care and Sleep Medicine, University of Cincinnati, Cincinnati, Ohio, USA.
- Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York, USA.
- Pulmonary Branch, National Heart, Lung, and Blood Institute (NHLBI), NIH, Bethesda, Maryland, USA.
ORCID-Profile: Stephen R Hammes
Förderung
- NCI NIH HHS
- NHLBI NIH HHS
Zitieren
APA
Gibbons, E., Taya, M., Wu, H., Lopa, S. H., Moss, J., Henske, E. P., McCormack, F. X., & Hammes, S. R. (2024). Glycoprotein non-metastatic melanoma protein B promotes tumor growth and is a biomarker for lymphangioleiomyomatosis. Endocrine-Related Cancer. https://doi.org/10.1530/erc-23-0312
Vancouver
Gibbons E, Taya M, Wu H, Lopa SH, Moss J, Henske EP, et al. Glycoprotein non-metastatic melanoma protein B promotes tumor growth and is a biomarker for lymphangioleiomyomatosis. Endocrine-Related Cancer. 2024. doi:10.1530/erc-23-0312
BibTeX
@article{Gibbons2024,
author = {Gibbons, Erin and Taya, Manisha and Wu, Huixing and Lopa, Samia H and Moss, Joel and Henske, Elizabeth P and McCormack, Francis X and Hammes, Stephen R},
title = {Glycoprotein non-metastatic melanoma protein B promotes tumor growth and is a biomarker for lymphangioleiomyomatosis},
journal = {Endocrine-Related Cancer},
year = {2024},
doi = {10.1530/erc-23-0312}
}
EUVIMED